NTRA logo

Natera Inc. (NTRA)

$273.40

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NTRA

Market cap

$39.64B

EPS

-1.13

P/E ratio

--

Price to sales

21.34

Dividend yield

--

Beta

1.547694

Price on NTRA

Previous close

$289.92

Today's open

$286.69

Day's range

$271.85 - $288.41

52 week range

$181 - $437.41

Profile about NTRA

CEO

Steven Chapman

Employees

6140

Headquarters

Austin, TX

Exchange

Nasdaq Global Select

Shares outstanding

145004521

Issue type

Common Stock

NTRA industries and sectors

Healthcare

Medical Diagnostics & Screening

News on NTRA

Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?

Natera dominates the molecular diagnostics market with high revenue growth and positive free cash flow. Tempus AI leverages a massive multimodal data library and artificial intelligence to drive precision medicine.

news source

The Motley Fool • Nov 19, 2026

news preview

Allspring Mid Cap Growth Fund Q3 2026 Contributors And Detractors

Allspring Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the third quarter. Top contributors include Twilio, Natera, Astera Labs, Cloudflare and Bloom Energy Corp. Top detractors include Carpenter Technology, RB Global, Viking Holdings, UL Solutions and Curtiss-Wright Corp.

news source

Seeking Alpha • Nov 19, 2026

news preview

Alger Capital Appreciation Fund Q3 2026 Portfolio Activity

Microsoft Corporation, NVIDIA Corporation, and Natera, Inc. were among the top contributors to performance. We believe Nvidia is a direct beneficiary of the AI infrastructure buildout given its strong competitive position, robust product roadmap, and expanding market opportunity. Western Digital Corporation, Nebius Group, and Astera Labs, Inc. were among the top detractors from performance.

news source

Seeking Alpha • Nov 18, 2026

news preview

HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards. The recognition highlights the impact of Natera's Signatera™ molecular residual disease (MRD) test on cancer care.The winners were announced live at the 2026 HLTH Conference in Las Vegas. This.

news source

Business Wire • Nov 17, 2026

news preview

Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029

Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement.

news source

MarketBeat • Nov 15, 2026

news preview

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera NASDAQ: NTRA CFO Mike Brophy said the company's newly announced $6 billion revenue target for 2029 is achievable with strong execution, as he outlined expectations for its Signatera cancer test and defended the immediate transition to a new CEO.

news source

MarketBeat • Nov 14, 2026

news preview

Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

Natera, Inc. ( NTRA ) 8th Annual Wolfe Research Healthcare Conference November 10, 2026 12:00 PM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Paige Chamberlain - Wolfe Research, LLC Presentation Paige Chamberlain Wolfe Research, LLC Hi, everyone. Thanks for being here.

news source

Seeking Alpha • Nov 11, 2026

news preview

Natera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference Transcript

Natera, Inc. ( NTRA ) 2026 UBS Global Healthcare Conference November 9, 2026 8:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good morning, everybody.

news source

Seeking Alpha • Nov 11, 2026

news preview

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte's investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT), incorporating Signatera as both a primary and seco.

news source

Business Wire • Nov 10, 2026

news preview

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.

news source

Zacks Investment Research • Nov 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Natera Inc.

Open an M1 investment account to buy and sell Natera Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NTRA on M1